N6-methyladenosine (m6A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis

Author:

Yuan Bao1,Zhou Jin2

Affiliation:

1. Beichen District Hospital of Traditional Chinese Medicine, Tianjin University of Chinese Medicine

2. Chu Hsien-I Memorial Hospital, Tianjin Medical University

Abstract

Abstract It has been reported that N6-methyladenosine (m6A) modification is mainly involved in clear-cell renal cell carcinoma (ccRCC) tumorigenesis. However, the regulatory mechanisms of m6A reader IGF2BP1 involved in ccRCC tumor energy metabolism are currently unknown. Results showed that the m6A reader IGF2BP1 exhibited significantly higher expression in ccRCC cells. Functionally, results by gainloss functional assay indicated that IGF2BP1 promoted the glucolytic characteristics, including glucose uptake, lactate production and extracellular acidification rate (ECAR). Mechanistically, IGF2BP1 recognizes the m6A modified sites on LDHA mRNA and enhances its mRNA stability, thereby accelerating tumor energy metabolism. Thus, our work reveals a novel facet of the m6A that promotes mRNA stability and highlights the functional importance of IGF2BP1 as m6A readers in post-transcriptional gene regulation.

Publisher

Research Square Platform LLC

Reference26 articles.

1. Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review;Cao H;Frontiers in surgery,2022

2. Kench JG, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology 2022.

3. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review;Liu YF;International immunopharmacology,2022

4. A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma;Pei D;Frontiers in oncology,2022

5. Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications;Vassiliou V;Anticancer research,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3